Similarly, the IDH1 and IDH2 inhibitors ivosidenib and enasidenib have shown promising results in clinical trials and have been approved for use in AML patients with IDH1 and IDH2 mutations, respectively [59, 60]. The gene discussed is IDH1; the disease is acute myeloid leukemia.